Status:
RECRUITING
Pharmacokinetics Vancomycin CVVHDF with OXiris Membrane
Lead Sponsor:
Mahidol University
Conditions:
AKI - Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study is a general pharmacokinetic investigation of vancomycin in patients receiving continuous veno-venous hemodiafiltration (CRRT) with the oXiris membrane. This membrane offers the added benef...
Detailed Description
This study monitors the levels of the maintenance dose of vancomycin in patients receiving continuous renal replacement therapy (CRRT) with the CVVHDF mode using the oXiris membrane. Blood samples wer...
Eligibility Criteria
Inclusion
- Patients aged more than 18 years.
- Admitted to the intensive care unit of Ramathibodi Hospital.
- Under continuous renal replacement therapy (CRRT) with CVVHDF using oXiris filter.
- Received vancomycin at least once after starting CRRT with CVVHDF using oXiris filter.
- who have signed the informed consent document.
Exclusion
- Patients with a history of vancomycin allergy.
- Patients expected to die within 24 hours after inclusion in study.
- Patients with circuit clotting occurring more than 2 hours during the blood draw period.
- Patients treated with extracorporeal membrane oxygenation (ECMO).
- Patients with a history of kidney transplantation.
- Pregnant or breastfeeding women.
- Patients who have decided to receive palliative care.
- Patients on hemodialysis or peritoneal dialysis.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06543940
Start Date
September 1 2024
End Date
December 31 2025
Last Update
January 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Facullty of Pharmacy Mahidol University
Bangkok, Payathi, Thailand, 10400